The detection rate of fungi of the Candida genus in patients with urogenital candidiasis and an analysis of the indicators of their antimycotic resistance over a ten-year period (2010–2020)
Objective. To study the detection rate of various fungal species of the Candida genus and their susceptibility to antifungal drugs over the period from 2010 to 2020.Rakhmatulina M.R., Tarasenko E.N.
Material and methods. Species identification was performed using 1927 Candida strains isolated from patients with urogenital candidiasis and their susceptibility to amphotericin B, clotrimazole, miconazole, ketoconazole, itraconazole, and fluconazole was determined.
Results. There was a decrease in the specific share of C. albicans in the total structure of identified fungi of the Candida genus (from 90.2% in 2010 to 66.7% in 2020) and a pronounced tendency to increase the detection rate of non-albicans Candida strains: C. glabrata from 6.5% to 16.7%, C. krusei from 2.2% to 7.4%, C. parapsilosis from 0 to 4.6%, C. tropicalis from 1.1% to 2.8%, and C. kefyr from 0% to 1.8%. C. albicans and C. glabrata showed a high susceptibility to amphotericin B (99.2–100% and 88.2–100%, respectively), ketoconazole (98.6–100% and 93.7–100%), and clotrimazole (92.7–100% and 87.5–100%); more than 80% of other Candida species were also susceptible to these drugs. Over the study period, C. albicans displayed a reduction in the level of susceptibility to fluconazole from 100% to 73.6% and to miconazole from 98.8% to 79.2%. In 2010–2020, there was a marked increase in itraconazole resistance in Candida species: C. albicans from 14.5% to 52.9%,
C. krusei from 0 to 37.5%, and C. parapsilosis from 0 to 60.0%; more than 50% of the C. glabrata, C. tropicalis, and C. kefyr isolates were resistant to itraconazole.
Conclusion. A dynamic a change in the species pattern of urogenital candidiasis pathogens, which is characterized by an increase in the proportion of non-albicans Candida species and by a decrease in the susceptibility of Candida fungi to a number of azole drugs (fluconazole, itraconazole, miconazole), necessitate the monitoring of antimycotic resistance and, if necessary, the optimization of the recommended therapy regimens for urogenital candidiasis according to the values obtained.
Keywords
urogenital candidiasis
resistance
Candida albicans
non-albicans Candida
clotrimazole
fluconazole
itraconazole
miconazole
References
- Желтикова Т.М. Мониторинг резистентности клинических штаммов дрожжей рода Candida к флуконазолу. Медицинский совет. 2017; 2: 70-4. [Zheltikova T.M. Monitoring of resistance of clinical strains of Candida yeast to fluconazole. Medicinskij sovet / Medical Council. 2017; (2): 70-4. (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2017-2-70-74.
- Mendling W., Brasch J., Cornely O.A., Effendy I., Friese K., Ginter-Hanselmayer G. et al. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses. 2015; 58(Suppl. 1): 1-15. https://dx.doi.org/10.1111/myc.12292.
- Colombo A.L., Júnior J.N.A., Guinea J. Emerging multidrug-resistant Candida species. Curr. Opin. Infect. Dis. 2017; 30(6): 528-38. https://dx.doi.org/10.1097/QCO.0000000000000411.
- Chen P.Y., Chuang Y.C., Wu U.I., Sun H.Y., Wang J.T., Sheng W.H. et al. Clonality of fluconazole-nonsusceptible Candida tropicalis in bloodstream infections, Taiwan, 2011-2017. Emerg. Infect. Dis. 2019; 25(9): 1660-7. https://dx.doi.org/10.3201/eid2509.190520.
- Fornari G., Vicente V.A., Gomes R.R., Muro M.D., Pinheiro R.L., Ferrari C. et al. Susceptibility and molecular characterization of Candida species from patients with vulvovaginitis. Braz. J. Microbiol. 2016; 47(2): 373-80. https://dx.doi.org/10.1016/j.bjm.2016.01.005.
- Межевитинова Е.А., Абакарова П.Р., Погосян Ш.М. Применение флуконазола у женщин репродуктивного возраста с вульвовагинальным кандидозом. Медицинский совет. 2018; 13: 96-102. [Mezhevitinova E.A., Abakarova P.R., Pogosjan Sh.M. Use of fluconazole in women of reproductive age with vulvovaginal candidiasis. Medicinskij sovet / Medical Council. 2018; (13): 96-102. (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2018-13-96-102.
- Bitew A., Abebaw Y. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. BMC Womens Health. 2018; 18(1): 94. https://dx.doi.org/10.1186/s12905-018-0607-z.
- Yan L., Wang X.D., Seyedmousavi S., Yuan J.N., Abulize P., Pan W.H. et al. Antifungal susceptibility profile of Candida albicans isolated from vulvovaginal candidiasis in Xinjiang Province of China. Mycopathologia. 2019; 184(3): 413-22. https://dx.doi.org/10.1007/s11046-018-0305-2.
- Sadeghi G., Ebrahimi-Rad M., Mousavi S.F., Shams-Ghahfarokhi M., Razzaghi-Abyaneh M.J. Emergence of non-Candida albicans species: epidemiology, phylogeny and fluconazole susceptibility profile. J. Mycol. Med. 2018; 28(1): 51-8. https://dx.doi.org/10.1016/j.mycmed.2017.12.008.
- Tsega A., Mekonnen F. Prevalence, risk factors and antifungal susceptibility pattern of Candida species among pregnant women at Debre Markos Referral Hospital, Northwest Ethiopia. BMC Pregnancy Childbirth. 2019; 19(1): 527. https://dx.doi.org/10.1186/s12884-019-2494-1.
- Brandolt T.M., Klafke G.B., Gonçalves C.V., Bitencourt L.R., Martinez A.M., Mendes J.F. et al. Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates. Braz. J. Microbiol. 2017; 48(1): 145-50. https://dx.doi.org/10.1016/j.bjm.2016.09.006.
- Wang F.J., Zhang D., Liu Z.H., Wu W.X., Bai H.H., Dong H.Y. Species distribution and in vitro antifungal susceptibility of vulvovaginal Candida isolates in China. Chin. Med. J. (Engl). 2016; 129(10): 1161-5. https://dx.doi.org/10.4103/0366-6999.181964.
- Khadka S., Sherchand J.B., Pokhrel B.M., Parajuli K., Mishra S.K., Sharma S. et al. Isolation, speciation and antifungal susceptibility testing of Candida isolates from various clinical specimens at a tertiary care hospital, Nepal. BMC Res. Notes. 2017; 10(1): 218. https://dx.doi.org/10.1186/s13104-017-2547-3.
- Спасибова Е.В., Савичева А.М. Оценка чувствительности in vitro дрожжеподобных грибов рода Candida и пробиотического штамма Lactobacillus rhamnosus к антимикотическим препаратам. Журнал акушерства и женских болезней. 2019; 68(5): 83-9. [Spasibova E.V., Savicheva A.M. Evaluation of in vitro sensitivity of yeast-like fungi of the genus Candida and probiotic strain Lactobacillus rhamnosus to antimycotic drugs. Zhurnal akusherstva i zhenskikh bolezney/ Journal of obstetrics and women’s diseases. 2019; 68(5): 83-9. (in Russian)]. https://dx.doi.org/10.17816/JOWD68583-89.
- Zhou X., Li T., Fan S. The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis. Mycoses. 2016; 59(7): 419-28. https://dx.doi.org/10.1111/myc.12485.
Received 26.06.2020
Accepted 08.07.2020
About the Authors
Margarita R. Rakhmatulina, MD, professor; Professor of the Department of dermatovenerology and cosmetology with a course of clinical laboratory diagnostics,State Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. Tel.: +7(916)203-10-03.
Е-mail: ra.marg@yandex.ru. ORCID: 0000-0003-3039-7769. 123098, Russia, Moscow, Zhivopisnaya str., 46.
Ellina N. Tarasenko, dermatovenerologist, Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology of the Moscow Department of Health.
Tel.: +7(926)401-13-29. Е-mail: ellina.tarasenko@mail.ru. ORCID: 0000-0001-8016-4109. 121170, Russia, Moscow, Kutuzovsky prospekt, 41.
For citation: Rakhmatulina M.R., Tarasenko E.N. The detection rate of fungi of the Candida genus in patients with urogenital candidiasis and an analysis of the indicators of their antimycotic resistance over a ten-year period (2010–2020).
Akusherstvo i Ginekologiya/ Obstetrics and Gynecology. 2020; 7: 159-165 (in Russian)
https://dx.doi.org/10.18565/aig.2020.7.159-165
Similar Articles
